- Revelation Biosciences Inc REVB announced biomarker data from a preclinical model of acute and chronic kidney disease, supporting the potential clinical utility of REVTx-300 previously announced in November last year.
- In this validated preclinical model, administration of REVTx-300 caused a significant reduction in circulating transforming growth factor-β (TGF-β) in a dose-dependent manner relative to the positive control group.
- In addition, REVTx-300 significantly increased circulating anti-inflammatory interleukin-10, hepcidin, and neutrophil gelatinase-associated lipocalin in all groups in a dose-dependent manner relative to the positive control group.
- There were no significant increases in markers of inflammation. Revelation plans to seek publication of the full results during 2023.
- Revelation originally released positive results from the preclinical model of acute kidney injury and chronic kidney disease.
- Additional analysis found that treatment with REVTx-300 significantly reduced new collagen deposition (fibrosis) in the renal cortex in a dose-dependent manner in the medium and high dose groups (42.1% reduction and 56.7%, respectively).
- Price Action: REVB shares are up 0.72% at $8.66 on the last check Tuesday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
